An advisory committee to the U.S. Food and Drug Administration recommended on Wednesday that the agency approve Teva Pharmaceutical Industries Ltd's

The panel voted unanimously that the drug should not be approved for children aged 12 to 17.

The FDA is not required to follow the advice of its expert advisory panels, but typically does so.

More on this...

Reslizumab is an antibody drug designed to be given intravenously once every four weeks.